アフターアワーズ： 24.46

Alkermes plc (ALKS)

Alkermes plc (ALKS) 最新ニュース

Alkermes plc (ALKS)

Alkermes plc (ALKS) 最新ニュース

Russell Investments Group Ltd. Trims Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe - Yahoo Singapore News

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences - PR Newswire

Teacher Retirement System of Texas Has $12.55 Million Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Multiple insiders bought Alkermes plc (NASDAQ:ALKS) stock earlier this year, a positive sign for shareholders - Yahoo Movies Canada

Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View - Yahoo Singapore News

Should You Buy Alkermes (ALKS) Ahead of Earnings? - Yahoo Movies Canada

Are Medical Stocks Lagging Alkermes (ALKS) This Year? - Yahoo Canada Shine On

Sale of Alkermes facility in Athlone is completed - Westmeath Independent

117,000 Shares in Alkermes plc (NASDAQ:ALKS) Purchased by LSV Asset Management - MarketBeat

Cwm LLC Has $55000 Stake in Alkermes plc (NASDAQ:ALKS) - Defense World

(ALKS) Technical Pivots with Risk Controls - Stock Traders Daily

Alkermes (ALKS) to Report Q4 Earnings: What's in Store? - Yahoo Lifestyle UK

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals - Simply Wall St

Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved - Yahoo New Zealand News

Are Medical Stocks Lagging Alkermes (ALKS) This Year? - Yahoo Singapore News

BioCryst (BCRX) Wins Japanese Approval for HAE Drug Orladeyo - Yahoo Singapore News

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo New Zealand News

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics - Yahoo Canada Shine On

New York State Common Retirement Fund Buys 11747 Shares of Alkermes plc (NASDAQ:ALKS) - Defense World

Alkermes plc (NASDAQ:ALKS) Expected to Post Q1 2025 Earnings of $0.43 Per Share - Defense World

Brokers Offer Predictions for Alkermes plc's Q1 2025 Earnings (NASDAQ:ALKS) - MarketBeat

Is There An Opportunity With Alkermes plc's (NASDAQ:ALKS) 49% Undervaluation? - Yahoo Movies Canada

Alkermes Advances Narcolepsy Drug Studies - Sleep Review

Alkermes (ALKS) Grants Teva License to Market Generic Drug - Yahoo Lifestyle UK

7 Analysts Assess Alkermes: What You Need To Know

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates

Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates - Zacks Investment Research

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk - The Malaysian Reserve

Earnings call: Alkermes reports solid Q1 2024 results, optimistic about pipeline - Investing.com

Yousif Capital Management LLC Takes Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates - Zacks Investment Research

Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates - Yahoo Finance

Alkermes plc (NASDAQ:ALKS) Short Interest Update - MarketBeat

Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

When the Price of (ALKS) Talks, People Listen - Stock Traders Daily

Handelsbanken Fonder AB Buys 147,000 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Alkermes' Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials - Sleep Review

Alkermes begins Phase II trial of ALKS 2680 for narcolepsy type 1 - Clinical Trials Arena

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy ... - PR Newswire

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition? - Zacks Investment Research

Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Alkermes to Report First Quarter Financial Results on May 1, 2024 - Marketscreener.com

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Alkermes Reports Positive Data From Schizophrenia Study - Yahoo Movies Canada

Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study

ALKSに似た銘柄